Allergan PLC. (AGN) Lowered to “Equal Weight” at Morgan Stanley

Morgan Stanley downgraded shares of Allergan PLC. (NYSE:AGN) from an overweight rating to an equal weight rating in a research report released on Wednesday. The brokerage currently has $228.00 price target on the stock, down from their previous price target of $284.00.

AGN has been the subject of several other reports. Cowen and Company set a $400.00 price objective on Allergan PLC. and gave the stock a buy rating in a research note on Thursday, June 8th. Sanford C. Bernstein restated an outperform rating on shares of Allergan PLC. in a research report on Thursday, May 25th. Mizuho decreased their target price on Allergan PLC. from $275.00 to $267.00 and set a buy rating on the stock in a research report on Friday, June 9th. Royal Bank Of Canada restated a buy rating and issued a $285.00 target price on shares of Allergan PLC. in a research report on Wednesday, September 6th. Finally, Cantor Fitzgerald assumed coverage on Allergan PLC. in a research report on Friday, June 16th. They issued a neutral rating and a $231.00 target price on the stock. One analyst has rated the stock with a sell rating, eight have issued a hold rating and fourteen have issued a buy rating to the stock. Allergan PLC. currently has a consensus rating of Buy and an average target price of $273.34.

Shares of Allergan PLC. (NYSE AGN) traded down 2.50% on Wednesday, reaching $204.76. 700,746 shares of the company traded hands. Allergan PLC. has a one year low of $184.50 and a one year high of $256.80. The company has a market capitalization of $68.45 billion, a PE ratio of 6.24 and a beta of 1.18. The firm has a 50-day moving average price of $229.79 and a 200 day moving average price of $236.07.

Allergan PLC. (NYSE:AGN) last released its earnings results on Thursday, August 3rd. The company reported $4.02 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $3.95 by $0.07. The firm had revenue of $4.01 billion for the quarter, compared to the consensus estimate of $3.95 billion. Allergan PLC. had a return on equity of 7.37% and a net margin of 79.17%. The company’s revenue for the quarter was up 8.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.35 EPS. Equities analysts forecast that Allergan PLC. will post $16.25 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Allergan PLC. (AGN) Lowered to “Equal Weight” at Morgan Stanley” was reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this article on another domain, it was stolen and reposted in violation of United States and international trademark & copyright legislation. The original version of this article can be accessed at https://www.chaffeybreeze.com/2017/09/21/allergan-plc-agn-lowered-to-equal-weight-at-morgan-stanley.html.

The firm also recently announced a quarterly dividend, which was paid on Friday, September 15th. Stockholders of record on Friday, August 18th were paid a dividend of $0.70 per share. The ex-dividend date of this dividend was Wednesday, August 16th. This represents a $2.80 annualized dividend and a dividend yield of 1.33%. Allergan PLC.’s dividend payout ratio is presently 9.95%.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Vanguard Group Inc. raised its holdings in shares of Allergan PLC. by 2.2% during the second quarter. Vanguard Group Inc. now owns 22,835,689 shares of the company’s stock valued at $5,551,128,000 after buying an additional 482,220 shares during the last quarter. Northern Trust Corp increased its stake in shares of Allergan PLC. by 8.8% during the second quarter. Northern Trust Corp now owns 4,492,944 shares of the company’s stock valued at $1,092,189,000 after acquiring an additional 364,722 shares during the period. Veritas Asset Management LLP acquired a new position in shares of Allergan PLC. during the first quarter valued at approximately $761,339,000. Edgewood Management LLC increased its stake in shares of Allergan PLC. by 7.0% during the first quarter. Edgewood Management LLC now owns 2,704,211 shares of the company’s stock valued at $646,090,000 after acquiring an additional 178,055 shares during the period. Finally, Epoch Investment Partners Inc. increased its stake in shares of Allergan PLC. by 3.8% during the first quarter. Epoch Investment Partners Inc. now owns 2,013,415 shares of the company’s stock valued at $481,045,000 after acquiring an additional 73,081 shares during the period. 82.02% of the stock is currently owned by hedge funds and other institutional investors.

About Allergan PLC.

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Analyst Recommendations for Allergan PLC. (NYSE:AGN)

Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply